Key Insights

Highlights

Treatment Research

4 treatments under study, led by Hypocaloric Mediterranean Diet

Research Leaders

9 sponsors active, led by Renal Pre-Competitive Consortium (RPC2)

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 3 (1)

Trial Status

Unknown1
Not Yet Recruiting1
Recruiting1
Enrolling By Invitation1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07904338Not Yet RecruitingPrimary

Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN

NCT01016613Enrolling By Invitation

Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center

NCT06858319Phase 3Recruiting

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

NCT05294770Not ApplicableUnknown

Dietary Intervention in Obesity-related Glomerulopathy

Showing all 4 trials

Research Network

Common Treatments

  • Hypocaloric Mediterranean Diet1
  • Optisource Plus Very Low Calorie Diet Treatment1
  • Blood Sample1
  • Zigakibart1

Active Sponsors

  • Renal Pre-Competitive Consortium (RPC2)1
  • St. John Health System, Michigan1
  • Novartis Pharma AG1
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1
  • Novartis Pharmaceuticals1

Top Investigators

Related Conditions

  • Glomerular Disease1
  • Kidney Diseases Chronic1
  • Glomerulonephritis1
  • Iga Nephropathy1
  • Membranoproliferative Glomerulonephritis Mpgn1

Activity Timeline